Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Associated Therapies: -

Clinical Trials

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Pazopanib
Drug: Paclitaxel

First Posted Date: 2015-03-09

Last Posted Date: 2023-09-06

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 118

Registration Number: NCT02383251

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Hôpital Henri Duffaut, Avignon, France
🇫🇷
Centre Jean Perrin, Clermont-ferrand, France

and more 33 locations

Pazopanib for Treating Uterine Leiomyosarcoma

Phase 2

Withdrawn

Conditions: Uterine Leiomyosarcoma

Interventions: Drug: Pazopanib

First Posted Date: 2015-03-04

Last Posted Date: 2015-11-18

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT02378142

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Conditions: Solid Tumors

First Posted Date: 2015-02-03

Last Posted Date: 2021-02-15

Lead Sponsor: Tracon Pharmaceuticals Inc.

Registration Number: NCT02354612

Locations: 🇺🇸
UCLA, Santa Monica, California, United States

Phase II Study of Pazopanib and Topotecan in Cervical Cancer

Phase 2

Withdrawn

Conditions: Cervical Cancer

Interventions: Drug: Pazopanib
Drug: Topotecan
Behavioral: Phone Call

First Posted Date: 2015-01-28

Last Posted Date: 2016-08-16

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02348398

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Phase 2

Withdrawn

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Pazopanib
Drug: Trametinib

First Posted Date: 2015-01-21

Last Posted Date: 2017-10-12

Lead Sponsor: Sarcoma Alliance for Research through Collaboration

Registration Number: NCT02342600

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: Pazopanib

First Posted Date: 2015-01-06

Last Posted Date: 2024-05-06

Lead Sponsor: Centre Antoine Lacassagne

Target Recruit Count: 51

Registration Number: NCT02331498

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, Cedex 2, France

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Phase 2

Conditions: Adverse Drug Event
Carcinoma, Renal Cell
Self Efficacy

Interventions: Drug: pazopanib

First Posted Date: 2014-12-24

Last Posted Date: 2014-12-24

Lead Sponsor: Southern China Urology Cancer Consortium

Target Recruit Count: 86

Registration Number: NCT02324803

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Phase 2

Completed

Conditions: Soft Tissue Sarcoma
Sarcoma, Soft Tissue

Interventions: Drug: Pazopanib

First Posted Date: 2014-11-25

Last Posted Date: 2020-08-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 56

Registration Number: NCT02300545

Locations: 🇺🇸
University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic - Phoenix, Phoenix, Arizona, United States

and more 4 locations

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2014-11-04

Last Posted Date: 2018-04-26

Lead Sponsor: Spanish Oncology Genito-Urinary Group

Target Recruit Count: 300

Registration Number: NCT02282579

Locations: 🇪🇸
Hospital Provincial de Pontevedra, Pontevedra, Spain
🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain

and more 31 locations

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Phase 2

Terminated

Conditions: Penile Squamous Cell Carcinoma Stage IV

Interventions: Drug: Pazopanib
Drug: Paclitaxel

First Posted Date: 2014-10-31

Last Posted Date: 2016-10-14

Lead Sponsor: Spanish Oncology Genito-Urinary Group

Target Recruit Count: 4

Registration Number: NCT02279576

Locations: 🇪🇸
Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain
🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital Universitario Lucus Augusti, Lugo, Spain

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy